Three Months Six Months
Ended June 30, Ended June 30,
-------------- --------------
2009 2008 2009 2008
---- ---- ---- ----
REVENUES
License fees $24,925 $25,522 $49,576 $39,293
Royalty income 63,858 84,772 143,103 160,346
Product sales 47,311 405 79,954 166,878
Other --- (15,000) 32,190 (15,000)
------- ------- ------ -------
Total Revenues 136,094 95,699 304,823 351,517
------- ------ ------- -------
COSTS AND
EXPENSES
Cost of goods
sold 8,921 119 14,998 137,734
Research and
development 854,460 887,544 1,629,879 1,742,760
Selling,
general and
administrative 1,835,487 1,341,235 4,060,106 2,234,470
Amortization 269,183 269,183 535,449 538,367
Depreciation 47,007 30,202 79,578 50,474
------ ------ ------ ------
Total Costs
and Expenses 3,015,058 2,508,283 6,320,010 4,703,805
--------- --------- --------- ---------
OPERATING
(LOSS) (2,878,964) (2,412,584) (6,015,187) (4,352,288)
Other Income
(Expense)
Interest and
miscellaneous
income 21,066 78,888 35,620 203,933
Loss on sale
of equipment
'/>"/>SOURCE ULURU Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine news :1.
ULURU Inc. to Present at UBS Global Life Sciences Conference 20072.
ULURU Inc. Announces Odd-Lot Buy Back Offer3.
ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update4.
ULURU Inc. Reports Third Quarter 2007 Results5.
ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent6.
ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 20087.
ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update8.
ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update9.
ULURU Inc. Announces the Launch Plan for Altrazeal(TM)10.
ULURU Inc. Reports First Quarter 2008 Financial Results11.
ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors